SALL4 is a newly identified oncogene that is involved in tumorigenesis, tumour growth, tumour metastasis and drug resistance through the regulation of various downstream genes.30 In AML, SALL4 directly interacts with β-catenin and induces the activation of Wnt/β-catenin signalling pathway, leading to the upregulation of the target genes of Wnt/β-catenin pathway including cyclin D1 and c-Myc.7 CD44 is also suggested as a downstream target gene of Wnt/β-catenin signalling. The gene discussed is CCND1; the disease is neoplasm.